This finding was largely driven by congestive heart failure. The practicing clinician should not abandon doxazosin completely because of the ALLHAT findings, although these findings are ...

Bristol Myers Squibb has reported disappointing results for its checkpoint inhibitor combination Opdualag in melanoma, dashing its hopes of moving the drug earlier in the treatment pathway.